CN117705713A - Sepsis detecting system - Google Patents
Sepsis detecting system Download PDFInfo
- Publication number
- CN117705713A CN117705713A CN202311715939.1A CN202311715939A CN117705713A CN 117705713 A CN117705713 A CN 117705713A CN 202311715939 A CN202311715939 A CN 202311715939A CN 117705713 A CN117705713 A CN 117705713A
- Authority
- CN
- China
- Prior art keywords
- concentration
- index
- sepsis
- reaction
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 59
- 238000001514 detection method Methods 0.000 claims abstract description 74
- 238000006243 chemical reaction Methods 0.000 claims description 75
- 102100032752 C-reactive protein Human genes 0.000 claims description 16
- 102000004889 Interleukin-6 Human genes 0.000 claims description 16
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 238000005286 illumination Methods 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102100038688 Cysteine-rich secretory protein LCCL domain-containing 2 Human genes 0.000 claims description 8
- 101000957715 Homo sapiens Cysteine-rich secretory protein LCCL domain-containing 2 Proteins 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 6
- 108010072542 endotoxin binding proteins Proteins 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 108010048233 Procalcitonin Proteins 0.000 claims description 2
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 2
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 238000012937 correction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a sepsis detection system, wherein a controller calculates the concentration of corresponding indexes based on an R value, a G value and a B value obtained by each index detection sheet, judges whether the concentration of each index is not in a normal concentration range of the corresponding index, judges that a person to be tested has the risk of being infected with sepsis when judging that at least more than half of the indexes are not in the normal concentration range, judges whether each index which is not in the normal concentration range is in a high risk concentration range, judges that the person to be tested has the risk of being infected with sepsis when at least one index is in the high risk range, judges that the person to be tested has the risk of being infected with sepsis when not having the concentration of at least one index in the high risk range, and judges that the person to be tested has no risk of being infected with sepsis when judging that at least more than half of the indexes are not in the normal concentration range.
Description
Technical Field
The invention relates to the technical field of sepsis detection, in particular to a sepsis detection system.
Background
Sepsis is defined as life threatening organ dysfunction caused by deregulation of the host's response to infection and septic shock. Traditional diagnostic methods utilize samples of a patient's blood, sputum, urine, wound secretions, etc. for bacterial/fungal culture, but such methods are time consuming and often delay accurate diagnosis and treatment of the patient. Moreover, the traditional detection equipment is huge and can only be carried out in a professional laboratory.
Disclosure of Invention
The invention provides a sepsis detection system aiming at the problems and the defects existing in the prior art.
The invention solves the technical problems by the following technical proposal:
the invention provides a sepsis detection system which is characterized by comprising a shell, wherein the left end of the inner bottom of the shell is a sample adding area, the right end of the inner bottom of the shell is a reaction area, a channel area is arranged between the left end and the right end of the inner bottom of the shell, a vertical left groove is formed in the left end of the front surface of the shell, a sample adding port corresponding to the sample adding area is formed in the inner bottom of the left groove, a vertical side groove is formed in the right side surface of the shell, an inlet and an outlet corresponding to the reaction area are formed in the inner bottom of the side groove, sample adding grooves are formed in the sample adding area, a plurality of reaction grooves are sequentially and abreast arranged in the reaction area along the longitudinal direction, index detection pieces for detecting specified indexes are respectively different in each reaction groove, sample adding channels corresponding to the reaction grooves one by one are formed in the channel area, the sample adding grooves are communicated with the corresponding reaction grooves through the sample adding channels, and color comparison plates are adhered to the outer sides of the reaction grooves positioned on the side edges of the reaction areas;
the left groove is internally embedded with a sample adding cover, the inner top of the left groove is fixedly provided with a left electric push rod, the push rod end of the left electric push rod is fixed with the top of the sample adding cover, the side groove is internally embedded with an access cover, the inner top of the side groove is fixedly provided with a side electric push rod, and the push rod end of the side electric push rod is fixed with the top of the access cover;
the high-definition camera, the illumination intensity sensor and the illuminating lamp which face the reaction area are fixed on the inner wall of the shell, a display screen, a switch, a sample adding control key, a detection control key and an in-out control key are embedded at the top of the shell, and a controller is arranged on the shell;
the controller is used for powering on after the switch is turned on, and controlling the left electric push rod to reset after receiving a sample adding instruction transmitted by the sample adding control key to drive the sample adding port cover to move upwards until the sample adding port cover does not cover the sample adding port, so that a worker can add samples from the sample adding port to the sample adding groove; starting timing after receiving a detection instruction transmitted by the detection control key, receiving an illumination intensity value in the shell transmitted by the illumination intensity sensor, controlling the lighting lamp to be turned on when the illumination intensity value is lower than the set illumination intensity, and controlling the high-definition camera to shoot a reaction area image after the timing time reaches the set reaction time; after receiving an access instruction transmitted by an access control key, the control side electric push rod resets to drive the access cover to move upwards until the access cover does not cover the access opening, so that a worker can take out the reacted index detection sheet from the access opening;
the controller is used for performing image processing on the reaction area image by utilizing an image processing technology so as to obtain an R value, a G value and a B value corresponding to the target color area on each index detection piece;
the controller is used for calculating the concentration of the corresponding index based on the R value, the G value and the B value obtained by each index detection sheet, judging whether the concentration of each index is not in the normal concentration range of the corresponding index, judging that more than half of the indexes are not in the corresponding normal concentration range, judging that the personnel to be tested have the risk of being infected with sepsis, judging whether the indexes not in the corresponding normal concentration range are in the high risk concentration range, judging that the personnel to be tested have the risk of being infected with sepsis when the concentration of at least one index is in the high risk range, controlling the display screen to display the information of the risk of being infected with sepsis, judging that the personnel to be tested have the risk of being infected with sepsis when the concentration of none of the indexes is in the high risk range, controlling the display screen to display the information of the risk of being infected with sepsis when the indexes not more than half of the indexes are not in the corresponding normal concentration range, and controlling the display screen to display the information of the risk of not being infected with sepsis.
The invention has the positive progress effects that:
the sepsis detection system designed by the invention has the advantages of relatively small volume, high detection efficiency and low cost, can detect only by few samples, and can provide detection results in a short time.
By using the system to detect the sepsis biomarker, the diagnosis time can be greatly reduced, so that measures can be taken in time before organ dysfunction occurs in patients, and the death rate of sepsis patients can be effectively reduced.
The detection results are classified, whether the personnel to be detected has the risk of infection and sepsis or not is judged based on the detected concentration of each index, and when the risk of infection and sepsis of the personnel to be detected is detected, whether the risk of infection and sepsis of the personnel to be detected is a moderate risk or a severe risk is further judged.
Drawings
Fig. 1 is a schematic structural diagram of a sepsis detecting system according to a preferred embodiment of the present invention.
Fig. 2 is a schematic view of the structure of the inner bottom of the housing according to the preferred embodiment of the invention.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
As shown in fig. 1 and 2, this embodiment provides a sepsis detection system, including casing 1, the inner bottom left end of casing 1 is for application of sample region 2, and the right-hand member is reaction region 3, is between the left and right ends and is channel region 4, has seted up application of sample groove 21 in the application of sample region 2, has excavated 5 reaction grooves side by side in proper order along longitudinal direction in the reaction region 3.
The front left end of casing 1 is offered and is vertical left recess 5, and the sample application mouth (not shown in the figure) corresponding with sample application groove 21 is offered to the interior bottom of left recess 5, and left recess 5 is embedded to be equipped with sample application mouth assorted sample application flap 6, and the interior top of left recess 5 is fixed with left electric putter 7, and the push rod end of left electric putter 7 is fixed mutually with the top of sample application flap 6, and wherein left electric putter 7 can select the miniature electric putter of current commercial market according to actual need. In addition, a left cover (not shown in the figure) can be detachably fixed on the front left end of the shell 1, the bottom of the left cover is positioned above the sample adding port, and the left cover covers the left electric push rod 7.
A vertical side groove 8 is formed in the right side surface of the shell 1, an inlet and outlet (not shown in the figure) corresponding to the reaction area 3 is formed in the inner bottom of the side groove 8, an inlet and outlet cover 9 matched with the inlet and outlet is embedded in the side groove 8, a side electric push rod 10 is fixed to the inner top of the side groove 8, the push rod end of the side electric push rod 10 is fixed to the top of the inlet and outlet cover 9, and the side electric push rod 10 can be a commercially available miniature electric push rod according to actual needs. In addition, a side cover (not shown) may be detachably fixed to the right side surface of the housing 1, and the bottom of the side cover is located above the inlet and outlet, and the side cover covers the side electric push rod 10.
Sample introduction channels 41 corresponding to the reaction tanks one by one are arranged in the channel area 4, and the sample introduction grooves 21 are communicated with the corresponding reaction tanks through the sample introduction channels 41.
The five reaction tanks are used for placing index detection pieces for detecting specified indexes, and indexes detected by the index detection pieces in each reaction tank are different. Specifically, the five reaction tanks are a first reaction tank 31, a second reaction tank 32, a third reaction tank 33, a fourth reaction tank 34 and a fifth reaction tank 35, respectively, the index detection sheet in the first reaction tank 31 is a PCT index detection sheet for detecting procalcitonin in a blood sample of a person to be tested, the index detection sheet in the second reaction tank 32 is a CRP index detection sheet for detecting C-reactive protein in the blood sample of the person to be tested, the index detection sheet in the third reaction tank 33 is an IL-6 index detection sheet for detecting interleukin-6 in the blood sample of the person to be tested, the index detection sheet in the fourth reaction tank 34 is a SAA index detection sheet for detecting serum amyloid a in the blood sample of the person to be tested, and the index detection sheet in the fifth reaction tank 35 is a CRISPLD2 index detection sheet for detecting endotoxin binding protein in the blood sample of the person to be tested, and the index detection sheet is a test paper. A colorimetric plate 36 is attached to the outside of the first reaction tank 31 in the reaction region 3.
The high-definition camera 11, the illumination intensity sensor 12 and the illuminating lamp 13 which face the reaction area 3 are fixed on the inner wall of the shell 1, a display screen 14, a switch 15, a sample adding control key 16, a detection control key 17 and an in-out control key 18 are embedded at the top of the shell 1, and a controller is also fixed in the shell 1.
The controller is used for powering up after switch 15 switches on, and the staff presses the application of sample control button 16, and application of sample control button 16 sends the application of sample instruction, and the controller is used for controlling left electric putter 7 to reset after receiving the application of sample instruction that application of sample control button 16, drives application of sample flap 6 and upwards moves, and until application of sample flap 6 does not cover and establishes the application of sample mouth, and the staff can follow application of sample mouth application of sample to application of sample groove 21 this moment. After sample addition, the blood sample of the person to be tested is communicated with the corresponding reaction tank from the sample addition tank 21 through the sample introduction channel 41.
The staff presses the detection control key 17, the detection control key 17 sends out a detection instruction, the controller is used for starting timing after receiving the detection instruction sent by the detection control key 17, receiving the illumination intensity value in the shell 1 sent by the illumination intensity sensor 12, controlling the illumination lamp 13 to be turned on when the illumination intensity value is lower than the set illumination intensity, providing a light source for the high-definition camera 11, and controlling the high-definition camera 11 to shoot a reaction area image after the timing time reaches the set reaction time.
The worker presses the access control key 18, the access control key 18 sends an access instruction, the controller is used for resetting the control side electric push rod 10 after receiving the access instruction sent by the access control key 18, and driving the access cover 9 to move upwards until the access cover 10 does not cover the access, and at the moment, the worker can take out reacted index detection pieces from the access.
The controller is used for carrying out image processing on the reaction area image by utilizing an image processing technology so as to obtain R value, G value and B value corresponding to the target color area on each index detection piece. Specifically, image noise filtering is performed on the reaction area image to filter noise in the reaction area image, color correction is performed on the noise-reduced reaction area image based on a CCM matrix to correct colors to the nearest color plate standard value on the colorimetric plate, BGR color space conversion and color normalization are performed on the color-corrected reaction area image, and areas in each corresponding set color range in the normalized reaction area image are extracted to be respectively used as target color areas, so that R values, G values and B values corresponding to the target color areas on each index detection piece are obtained.
The controller is configured to calculate the concentration of the corresponding index based on the R value, G value, and B value obtained by each index detection piece using a formula.
The formula is: c=k1×b-value+k2×g-value+k3×r-value
The index is one of procalcitonin-PCT, C reactive protein-CRP, interleukin-6-IL-6, serum amyloid A-SAA and endotoxin binding protein-CRISPLD 2, C represents the concentration of a certain index, B-value represents the B value corresponding to the target color region corresponding to the index, k1 represents the proportionality coefficient of the B-value and the concentration of the index, G-value represents the G value corresponding to the target color region corresponding to the index, k2 represents the proportionality coefficient of the G-value and the concentration of the index, R-value represents the R value corresponding to the target color region corresponding to the index, and k3 represents the proportionality coefficient of the R-value and the concentration of the index.
The controller is used for judging whether the PCT concentration is not in the normal concentration range, whether the CRP concentration is not in the normal concentration range, whether the IL-6 concentration is not in the corresponding normal concentration range, whether the SAA concentration is not in the corresponding normal concentration range and whether the CRISPLD2 concentration is not in the corresponding normal concentration range, judging that the personnel to be tested is at risk of being infected with sepsis when judging that at least three indexes are not in the corresponding normal concentration range, otherwise judging that the personnel to be tested is not at risk of being infected with sepsis, controlling the display screen 14 to display information that the personnel to be tested is not at risk of being infected with sepsis, and simultaneously displaying the PCT concentration, the CRP concentration, the IL-6 concentration, the SAA concentration and the CRISPLD2 concentration.
The controller is used for further judging whether each index which is not in the corresponding normal concentration range is in the high risk concentration range when judging that the person to be tested is at risk of infection sepsis, judging that the person to be tested is at risk of severe infection sepsis when at least one index is in the high risk range, controlling the display screen 14 to display information of the risk of severe infection sepsis of the person to be tested, and simultaneously displaying PCT concentration, CRP concentration, IL-6 concentration, SAA concentration and CRISPLD2 concentration, wherein the index concentration which is in the corresponding high risk concentration range is displayed in a first specific form (such as yellow), the index concentration which is not in the corresponding high risk concentration range and is not in the corresponding normal concentration range is displayed in a second specific form (such as red), otherwise judging that the person to be tested is at risk of moderate infection sepsis, controlling the display screen 14 to display information of the risk of moderate infection sepsis of the person to be tested, and simultaneously displaying PCT concentration, CRP concentration, IL-6 concentration, SAA concentration and CRISPLD2 concentration, wherein the index concentration which is not in the corresponding normal concentration range is displayed in the second specific form.
Wherein, the normal concentration range and the abnormal concentration range of PCT, CRP, IL-6, SAA and CRISPLD2 in human body are as follows:
PCT: normal concentration <0.05ng/ml, high risk not less than 0.5ng/ml;
CRP: normal concentration is less than 3ug/ml, and high risk is more than or equal to 20mg/ml;
IL-6: normal concentration <25pg/ml, high risk > 150pg/ml;
SAA: normal concentration is less than 10ug/ml, and high risk is more than or equal to 500ug/ml;
crisp 2: normal concentration 384-790ug/ml, high risk not less than 1000ug/ml.
After the detection is finished, a worker presses the sample adding control key 16 for a long time, the sample adding control key 16 sends a sample adding ending instruction, and the controller is used for controlling the left electric push rod 7 to extend after receiving the sample adding ending instruction sent by the sample adding control key 16, so as to drive the sample adding port cover 6 to move downwards until the sample adding port cover 6 covers the sample adding port.
After the detection is finished, a worker presses the access control key 18 for a long time, the access control key 18 sends an access finishing instruction, and the controller is used for controlling the side electric push rod 10 to stretch after receiving the access finishing instruction sent by the access control key 18, so as to drive the access cover 9 to move downwards until the access cover 10 covers the access.
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that these are by way of example only, and the scope of the invention is defined by the appended claims. Various changes and modifications to these embodiments may be made by those skilled in the art without departing from the principles and spirit of the invention, but such changes and modifications fall within the scope of the invention.
Claims (10)
1. The sepsis detection system is characterized by comprising a shell, wherein the left end of the inner bottom of the shell is a sample adding area, the right end of the inner bottom of the shell is a reaction area, a channel area is arranged between the left end and the right end of the inner bottom of the shell, a vertical left groove is formed in the left end of the front of the shell, a sample adding port corresponding to the sample adding area is formed in the inner bottom of the left groove, a vertical side groove is formed in the right side surface of the shell, an inlet and an outlet corresponding to the reaction area are formed in the inner bottom of the side groove, sample adding grooves are formed in the sample adding area, a plurality of reaction grooves are sequentially dug side by side in the reaction area along the longitudinal direction, index detection pieces for detecting specified indexes are placed in each reaction groove, indexes detected by the index detection pieces in each reaction groove are different, sample introducing channels corresponding to the reaction grooves one by one are formed in the channel area, the sample adding grooves are communicated with the corresponding reaction grooves through the sample introducing channels, and color comparison plates are adhered to the outer sides of the reaction grooves positioned on the sides of the reaction areas;
the left groove is internally embedded with a sample adding cover, the inner top of the left groove is fixedly provided with a left electric push rod, the push rod end of the left electric push rod is fixed with the top of the sample adding cover, the side groove is internally embedded with an access cover, the inner top of the side groove is fixedly provided with a side electric push rod, and the push rod end of the side electric push rod is fixed with the top of the access cover;
the high-definition camera, the illumination intensity sensor and the illuminating lamp which face the reaction area are fixed on the inner wall of the shell, a display screen, a switch, a sample adding control key, a detection control key and an in-out control key are embedded at the top of the shell, and a controller is arranged on the shell;
the controller is used for powering on after the switch is turned on, and controlling the left electric push rod to reset after receiving a sample adding instruction transmitted by the sample adding control key to drive the sample adding port cover to move upwards until the sample adding port cover does not cover the sample adding port, so that a worker can add samples from the sample adding port to the sample adding groove; starting timing after receiving a detection instruction transmitted by the detection control key, receiving an illumination intensity value in the shell transmitted by the illumination intensity sensor, controlling the lighting lamp to be turned on when the illumination intensity value is lower than the set illumination intensity, and controlling the high-definition camera to shoot a reaction area image after the timing time reaches the set reaction time; after receiving an access instruction transmitted by an access control key, the control side electric push rod resets to drive the access cover to move upwards until the access cover does not cover the access opening, so that a worker can take out the reacted index detection sheet from the access opening;
the controller is used for performing image processing on the reaction area image by utilizing an image processing technology so as to obtain an R value, a G value and a B value corresponding to the target color area on each index detection piece;
the controller is used for calculating the concentration of the corresponding index based on the R value, the G value and the B value obtained by each index detection sheet, judging whether the concentration of each index is not in the normal concentration range of the corresponding index, judging that more than half of the indexes are not in the corresponding normal concentration range, judging that the personnel to be tested have the risk of being infected with sepsis, judging whether the indexes not in the corresponding normal concentration range are in the high risk concentration range, judging that the personnel to be tested have the risk of being infected with sepsis when the concentration of at least one index is in the high risk range, controlling the display screen to display the information of the risk of being infected with sepsis, judging that the personnel to be tested have the risk of being infected with sepsis when the concentration of none of the indexes is in the high risk range, controlling the display screen to display the information of the risk of being infected with sepsis when the indexes not more than half of the indexes are not in the corresponding normal concentration range, and controlling the display screen to display the information of the risk of not being infected with sepsis.
2. The sepsis detection system according to claim 1, wherein five reaction tanks are sequentially arranged side by side in the reaction area along the longitudinal direction, the five reaction tanks are respectively a first reaction tank, a second reaction tank, a third reaction tank, a fourth reaction tank and a fifth reaction tank, the index detection sheet in the first reaction tank is a PCT index detection sheet for detecting procalcitonin in a blood sample of a person to be detected, the index detection sheet in the second reaction tank is a CRP index detection sheet for detecting C-reactive protein in the blood sample of the person to be detected, the index detection sheet in the third reaction tank is an IL-6 index detection sheet for detecting interleukin-6 in the blood sample of the person to be detected, the index detection sheet in the fourth reaction tank is a SAA index detection sheet for detecting serum amyloid a in the blood sample of the person to be detected, and the index detection sheet in the fifth reaction tank is a crild 2 index detection sheet for detecting endotoxin binding protein in the blood sample of the person to be detected.
3. A sepsis detection system according to claim 2, wherein the controller is operable to calculate the concentration of the corresponding index based on the R, G and B values obtained for each index detection patch using a formula;
the formula is: c=k1×b-value+k2×g-value+k3×r-value
The index is one of procalcitonin-PCT, C reactive protein-CRP, interleukin-6-IL-6, serum amyloid A-SAA and endotoxin binding protein-CRISPLD 2, C represents the concentration of a certain index, B-value represents the B value corresponding to the target color region corresponding to the index, k1 represents the proportionality coefficient of the B-value and the concentration of the index, G-value represents the G value corresponding to the target color region corresponding to the index, k2 represents the proportionality coefficient of the G-value and the concentration of the index, R-value represents the R value corresponding to the target color region corresponding to the index, and k3 represents the proportionality coefficient of the R-value and the concentration of the index.
4. A sepsis detection system according to claim 3, wherein the controller is configured to determine whether PCT concentration is not within a normal concentration range, CRP concentration is not within a normal concentration range, IL-6 concentration is not within a corresponding normal concentration range, SAA concentration is not within a corresponding normal concentration range, and crisp 2 concentration is not within a corresponding normal concentration range, determine that a person under test is at risk of sepsis, if at least three indices are determined not to be within a corresponding normal concentration range, otherwise determine that a person under test is not at risk of sepsis, control the display screen to display information that a person under test is not at risk of sepsis, and simultaneously display PCT concentration, CRP concentration, IL-6 concentration, SAA concentration, and crisp 2 concentration;
the controller is used for further judging whether each index which is not in the corresponding normal concentration range is in the high risk concentration range when judging that the personnel to be tested is at risk of sepsis, judging that the personnel to be tested is at risk of sepsis due to severe infection when at least one index is in the high risk range, controlling the display screen to display information of the risk of sepsis due to severe infection of the personnel to be tested, simultaneously displaying PCT concentration, CRP concentration, IL-6 concentration, SAA concentration and CRISPLD2 concentration, wherein the index concentration which is in the corresponding high risk concentration range is displayed in a first specific form, the index concentration which is not in the corresponding high risk concentration range and is not in the corresponding normal concentration range is displayed in a second specific form, otherwise judging that the personnel to be tested is at risk of sepsis due to moderate infection, controlling the display screen to display information of the risk of sepsis due to severe infection of the personnel to sepsis, and simultaneously displaying PCT concentration, CRP concentration, IL-6 concentration, SAA concentration and CRISPLD2 concentration, wherein the index concentration which is not in the corresponding normal concentration range is displayed in the second specific form.
5. A sepsis detection system according to claim 4, wherein the normal and abnormal concentration ranges of PCT, CRP, IL-6, SAA and crisp 2 in humans are:
PCT: normal concentration <0.05ng/ml, high risk not less than 0.5ng/ml;
CRP: normal concentration is less than 3ug/ml, and high risk is more than or equal to 20mg/ml;
IL-6: normal concentration <25pg/ml, high risk > 150pg/ml;
SAA: normal concentration is less than 10ug/ml, and high risk is more than or equal to 500ug/ml;
crisp 2: normal concentration 384-790ug/ml, high risk not less than 1000ug/ml.
6. A sepsis detection system according to claim 1, wherein the controller is configured to perform image noise filtering on the reaction region image to filter noise in the reaction region image, perform color correction on the noise-reduced reaction region image based on the CCM matrix to correct the color to a color plate standard value closest to the color plate, perform BGR color space conversion and color normalization on the color-corrected reaction region image, and extract regions in respective corresponding set color ranges in the normalized reaction region image as respective target color regions, so as to obtain R values, G values, and B values corresponding to the target color regions on the respective index detection plates.
7. A sepsis detection system according to claim 1, wherein a left cover is detachably secured to the front left end of the housing, the bottom of the left cover being located above the sample addition port, the left cover housing a left electric push rod.
8. A sepsis detection system according to claim 1 in which a side cover is removably secured to the right side of the housing, the bottom of the side cover being located above the access opening, the side cover housing a side electric push rod.
9. A sepsis detection system according to claim 1, wherein the controller is fixed within the housing.
10. A sepsis detection system according to claim 1, wherein the left and side electric pushers are miniature electric pushers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311715939.1A CN117705713B (en) | 2023-12-13 | 2023-12-13 | Sepsis detecting system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311715939.1A CN117705713B (en) | 2023-12-13 | 2023-12-13 | Sepsis detecting system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117705713A true CN117705713A (en) | 2024-03-15 |
| CN117705713B CN117705713B (en) | 2024-06-11 |
Family
ID=90143729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311715939.1A Active CN117705713B (en) | 2023-12-13 | 2023-12-13 | Sepsis detecting system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117705713B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0115459A2 (en) * | 1983-01-26 | 1984-08-08 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
| CN101246163A (en) * | 2008-01-29 | 2008-08-20 | 广州益善生物技术有限公司 | Pyemia early diagnosis liquid phase chip and method for producing the same |
| US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US20100292131A1 (en) * | 2007-11-16 | 2010-11-18 | Pronota N.V. | Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof |
| US20120149785A1 (en) * | 2008-10-09 | 2012-06-14 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe | Method of estimating sepsis risk in an individual with infection |
| US20150177260A1 (en) * | 2012-07-23 | 2015-06-25 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
| CN207611054U (en) * | 2017-12-28 | 2018-07-13 | 深圳市博卡生物技术有限公司 | The test strips and its detection card of joint-detection IL-6/PCT/CRP/SAA |
| CN108722507A (en) * | 2018-06-21 | 2018-11-02 | 微粒云科技（北京）有限公司 | A kind of inflammation four marker magnetic particle microflow controlled biochips, detection methods |
| CN111721941A (en) * | 2020-07-17 | 2020-09-29 | 南方科技大学 | Device for judging sepsis infection condition and application thereof |
| CN113189349A (en) * | 2021-06-15 | 2021-07-30 | 上海交通大学医学院附属瑞金医院 | Micro-fluidic chip for detecting multiple infection markers in peripheral blood by multi-channel ELISA (enzyme-linked immunosorbent assay) |
| CN116413443A (en) * | 2023-03-06 | 2023-07-11 | 武汉大学 | Application of serum testosterone as marker in preparation of kit for diagnosis and prognosis prediction of sepsis myocardial dysfunction |
-
2023
- 2023-12-13 CN CN202311715939.1A patent/CN117705713B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0115459A2 (en) * | 1983-01-26 | 1984-08-08 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
| US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US20100292131A1 (en) * | 2007-11-16 | 2010-11-18 | Pronota N.V. | Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof |
| CN101246163A (en) * | 2008-01-29 | 2008-08-20 | 广州益善生物技术有限公司 | Pyemia early diagnosis liquid phase chip and method for producing the same |
| US20120149785A1 (en) * | 2008-10-09 | 2012-06-14 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe | Method of estimating sepsis risk in an individual with infection |
| US20150177260A1 (en) * | 2012-07-23 | 2015-06-25 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
| CN207611054U (en) * | 2017-12-28 | 2018-07-13 | 深圳市博卡生物技术有限公司 | The test strips and its detection card of joint-detection IL-6/PCT/CRP/SAA |
| CN108722507A (en) * | 2018-06-21 | 2018-11-02 | 微粒云科技（北京）有限公司 | A kind of inflammation four marker magnetic particle microflow controlled biochips, detection methods |
| CN111721941A (en) * | 2020-07-17 | 2020-09-29 | 南方科技大学 | Device for judging sepsis infection condition and application thereof |
| CN113189349A (en) * | 2021-06-15 | 2021-07-30 | 上海交通大学医学院附属瑞金医院 | Micro-fluidic chip for detecting multiple infection markers in peripheral blood by multi-channel ELISA (enzyme-linked immunosorbent assay) |
| CN116413443A (en) * | 2023-03-06 | 2023-07-11 | 武汉大学 | Application of serum testosterone as marker in preparation of kit for diagnosis and prognosis prediction of sepsis myocardial dysfunction |
Non-Patent Citations (4)
| Title |
|---|
| BIRSEN UCAR 等: "Serum Amyloid A, Procalcitonin, Tumor Necrosis Factor-α, and Interleukin-1β Levels in Neonatal Late-Onset Sepsis", CLINICAL STUDY, 31 August 2008 (2008-08-31), pages 1 - 7, XP002575875, DOI: 10.1155/2008/737141 * |
| ERIC DAYER 等: "Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases", NATURE CLINICAL PRACTICE RHEUMATOLOGY, vol. 3, no. 9, 30 September 2007 (2007-09-30), pages 512 - 520 * |
| TAO WANG 等: "CRISPLD2 Is Expressed at Low Levels during Septic Shock and Is Associated with Procalcitonin", PLOS ONE, vol. 8, no. 6, 14 June 2013 (2013-06-14), pages 1 - 7 * |
| 杨辉;罗倩;陈君灏;杨森;张珏;: "血清PCT、CRP及内毒素在细菌性血流感染所致脓毒症患者中的早期诊断价值", 现代生物医学进展, no. 02, 20 January 2017 (2017-01-20), pages 338 - 341 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117705713B (en) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170248592A1 (en) | System and Method for Integration of Mobile Device Imaging with Microchip Elisa | |
| CA2788636C (en) | Il-6 detection based early diagnosis and prediction of systemic inflammatory response syndrome and sepsis in asymptomatic patients | |
| CN101460090B (en) | Methods for characterizing tissues | |
| CN117705713B (en) | Sepsis detecting system | |
| CN103308696A (en) | Brucella rapid detection kit based on mass-spectrometric technique | |
| Smith et al. | The putative role of MALDI-MSI in the study of membranous nephropathy | |
| CN109828106B (en) | Full-automatic immunofluorescence analytical apparatus | |
| CN114739991A (en) | Urine dryness chemical routine detection method and detection device | |
| CN117491284B (en) | Instant sepsis detection equipment based on microfluidic technology | |
| CN117274295A (en) | Novel array type urine test paper instant detection and analysis method | |
| Higby et al. | A comparison between two screening methods for detection of microproteinuria | |
| CN103344695A (en) | Kit for rapid mass spectrometric detection of leptospira | |
| CN109946462B (en) | Application of 4210Da polypeptide as marker in diagnosis of liver cancer, liver cirrhosis and chronic hepatitis B | |
| CN105461605A (en) | Compound for detecting cancer | |
| KR20020033093A (en) | Methods for predicting and/or diagnosing the risk of gastric cancer | |
| CN104502254A (en) | Automatic cell cloning survival rate detection device and detection method thereof | |
| RU49276U1 (en) | TEST SYSTEM FOR THE DETERMINATION OF HIDDEN BLOOD IN EXTRACTS FROM BREAST | |
| RU2814399C1 (en) | Method of diagnostics of kidney damage in children with vesicoureteral reflux | |
| Hamilton et al. | P216 Anti-drug antibodies to infliximab: A comparison of free anti-drug antibody measurement | |
| US20230003730A1 (en) | A viral exposure signature for detection of early stage hepatocellular carcinoma | |
| CN215931680U (en) | Urine protein detector | |
| CN113884684B (en) | Construction method of active tuberculosis multiunit chemical integration marker, kit and detection model | |
| Valeeva et al. | Variability of urine proteome in healthy humans during a 105-day isolation in a pressurized compartment | |
| CN210037826U (en) | Protective shell for full-automatic immunofluorescence analysis device | |
| De Castro et al. | P320 Accuracy of faecal calprotectin level to select patients with inflammatory bowel disease for a chromoendoscopy surveillance programme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |